Law360, New York (March 10, 2009, 12:00 AM ET) -- Sepracor Inc. has reached a settlement agreement with Barr Laboratories Inc. that will put to rest nearly two years of feuding over a group of patents covering the inhaled asthma treatment Xopenex, which Teva Pharmaceuticals USA Inc. subsidiary Barr will be allowed to market generically in 2013.
Under the terms of the deal, Marlborough, Mass.-based Sepracor said Tuesday it would grant a nonexclusive license to Barr — which was acquired by Teva in December — that would give it the green light to launch generic versions...
Sepracor Makes Peace With Barr Over Xopenex
To view the full article, take a free trial now.
